AnswersPublished15 sources
Why p53-Mutant Cancers Can Evade T-Cell Detection
A p53 mutation can be present in a cancer yet remain effectively invisible to T cells: only 5 of 175 predicted wild type p53 peptides were robustly displayed by HLA in the study, underscoring that DNA mutations do not... The proposed “immunopeptidome shift” would try to preserve or stabilize tumor peptides on the ce...
Published byEdited with GPT-5.6 TerraImages generated with GPT Image 2
Research answer
Key takeaways
- A p53 mutation can be present in a cancer yet remain effectively invisible to T cells: only 5 of 175 predicted wild type p53 peptides were robustly displayed by HLA in the study, underscoring that DNA mutations do not...
- The proposed “immunopeptidome shift” would try to preserve or stabilize tumor peptides on the cell surface, but ERAP1 inhibitors, HLA binding modifiers, and splicing based approaches remain preclinical.
AI Prompt
openai.comCreate a landscape editorial hero image for this Studio Global article: How did the Dana-Farber Cancer Institute study published in Immunity explain why cancers with p53 mutations—found in roughly half of human m. Article summary: The study’s central explanation is that a p53 mutation is not automatically a visible T-cell target. T cells recognize short peptides displayed by HLA molecules—not tumor DNA itself—and many p53-derived mutant peptides n. Topic tags: general, government, general web. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts with fake n
T cells do not inspect a tumor’s DNA directly. They inspect short protein fragments, called peptides, that are held on the cell surface by human leukocyte antigen (HLA) molecules. The full set of these peptide–HLA displays is the immunopeptidome. Dana-Farber researchers argue that this presentation step helps explain why cancers carrying common TP53 mutations can still escape T-cell recognition: the mutation may exist in the tumor genome without producing a stable, sufficiently abundant surface target. 9
A mutation is not automatically an antigen
A p53 mutation can appear to be an attractive immunotherapy target because it is cancer-specific and some hotspot mutations recur across patients. But a T cell can respond only if the corresponding mutant peptide is generated inside the tumor cell, transported and trimmed appropriately, loaded onto a compatible HLA molecule, and retained on the cell surface long enough for recognition. 9
12
The Dana-Farber team used ultrasensitive mass spectrometry to measure peptides that were actually displayed rather than relying solely on computational prediction. Of 175 predicted wild-type p53 peptide candidates, only five were robustly displayed. The result shows a major gap between a sequence-based prediction and the peptides that are genuinely available to immune cells on tumor cells. 9
How p53-mutant tumors lose T-cell visibility
The study identified several points at which a potentially useful p53-derived target can disappear:
- Poor antigen processing: A mutant protein sequence may not be cut into the required peptide, or its fragments may be trimmed or transported inefficiently before HLA loading.
9
12
- Weak HLA binding: Even a correctly generated peptide may bind its matching HLA molecule too weakly to remain displayed at the cell surface.
- ERAP1 over-trimming: The researchers reported that ERAP1, an endoplasmic-reticulum aminopeptidase involved in preparing peptides for HLA presentation, could destroy an otherwise immunogenic p53 neoepitope. In that setting, peptide trimming removed the immune target rather than preparing it for display.
- Loss of antigen-presenting HLA: In established tumors, immune selection can also favor loss of the HLA allele that presents a detectable p53 neoepitope.
Together, these mechanisms mean that a tumor may carry a shared p53 hotspot mutation but display little or none of the peptide–HLA complex needed for a T cell to find it.
Why p53 R175H is a revealing example
The common p53 R175H mutation illustrates the distinction between immune recognition in principle and effective tumor-cell presentation in practice. Earlier studies identified HLA-A*02:01-restricted recognition of the R175H peptide epitope and found T-cell receptors capable of recognizing it. 16
6
However, the Dana-Farber work found that the R175H/HLA-A*02:01 complex has very weak MHC affinity and therefore short-lived cell-surface expression. 12 Related research has likewise reported extremely low density of the R175H peptide–HLA complex on cancer-cell surfaces, even where an engineered bispecific approach could activate T cells against cells that presented it in laboratory experiments.
3
That helps resolve an important apparent contradiction: a peptide can activate T cells in an experimental assay, especially when peptide is supplied externally, while being too scarce or unstable on a real tumor cell to support durable immune attack.
The proposed solution: shift the immunopeptidome
Rather than focusing only on making T cells more active, the researchers propose an “immunopeptidome shift”: alter which peptides survive antigen processing and are displayed by HLA on tumor cells. 9
Potential approaches include:
- ERAP1 inhibition to preserve neoepitopes that would otherwise be over-trimmed or destroyed.
- Small molecules that alter HLA–peptide binding to stabilize weakly bound mutant peptides and potentially extend their surface display.
- RNA-splicing drugs that may create or expose alternative tumor-selective peptide products for HLA presentation.
If such interventions make more tumor-specific peptide–HLA complexes available, they could potentially be combined with checkpoint inhibitors, therapeutic cancer vaccines, or engineered T-cell receptor therapies. The premise is straightforward: these immune therapies need a real target on the tumor cell, not simply a mutation identified by genomic sequencing. 9
What this could mean for “cold” tumors
The work has potential relevance for cancers that often show weak T-cell infiltration or limited responses to immunotherapy, including pancreatic, prostate, ovarian, brain, and breast tumors. The goal is not merely to increase inflammation broadly, but to make tumor cells display targets that T cells can distinguish and attack. 9
This remains a preclinical strategy, not an established treatment. Whether immunopeptidome-shifting therapies can safely increase tumor visibility without harmful effects on normal tissues will depend on the particular mutation, the patient’s HLA type, peptide selectivity, toxicity, and the treatment combination. Dana-Farber is continuing to investigate this direction through its DYNAMO initiative. 9
The study’s broader lesson is that cancer immunotherapy cannot stop at identifying mutations. For a mutation to become a useful target, researchers must verify that its peptide is actually processed, displayed by the relevant HLA molecule, and present at a level that immune cells can detect.
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
People also ask
What is the short answer to "Why p53-Mutant Cancers Can Evade T-Cell Detection"?
A p53 mutation can be present in a cancer yet remain effectively invisible to T cells: only 5 of 175 predicted wild type p53 peptides were robustly displayed by HLA in the study, underscoring that DNA mutations do not...
What are the key points to validate first?
A p53 mutation can be present in a cancer yet remain effectively invisible to T cells: only 5 of 175 predicted wild type p53 peptides were robustly displayed by HLA in the study, underscoring that DNA mutations do not... The proposed “immunopeptidome shift” would try to preserve or stabilize tumor peptides on the cell surface, but ERAP1 inhibitors, HLA binding modifiers, and splicing based approaches remain preclinical.
Sources
aacrjournals.orgImmunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
pmc.ncbi.nlm.nih.govStructural basis for oligoclonal T cell recognition of a shared p53 ...